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Abstract 
Background: Double-negative (DN) T cells could delay the onset and the progression of autoimmune diabetes, yet 
they were less efficient on reversing autoimmune diabetes. The aim of this study was to investigate whether the com-
bination of DN T cells and anti-thymocyte serum (ATS) could reverse new-onset diabetes in NOD mice.
Methods: The regulation of different subsets of T cells in vitro and in vivo by ATS and DN T cells were examined using 
flow cytometry. At the day of diabetes onset, ATS was administered on the same day and 2 days later, and DN T cells 
were transferred at day 7. The reversion of diabetes was assessed by monitoring blood glucose levels.
Results: The efficacy of inhibition of DN T cells on CD8+ T cells was lower than that on CD4+ T cells both in vitro 
and in vivo. ATS resulted in a significant depletion of CD8+ T cells, while DN T cells were less sensitive to ATS deple-
tion. 80 % diabetic NOD mice achieved long term (6 months) reversion of diabetes by combined ATS and DN T cells 
treatment, compared to 16 % in ATS single treatment and none in DN T cell single treatment. DN T cells preferentially 
resided in spleen and pancreatic draining lymph nodes in ATS plus DN T cells treated NOD mice.
Conclusions: DN T cells plus ATS therapy show promising reversion effects on diabetic NOD mice due to a shift of 
balance from a destructive T cell response to one that favors DN T cell regulation.
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Background
Type 1 diabetes is an autoimmune disease in which the 
patient fails to develop or loses tolerance to self-antigens 
at a young age. Consequently, auto-aggressive T cells 
gradually infiltrate the pancreas and selectively destroy 
the insulin-producing beta cells, eventually leading to 
overt diabetes [1, 2]. Both CD4+ and CD8+ cytotoxic T 
lymphocytes contribute to beta cell killing [3–5]. One 
mechanism that may lead to the development of type 1 
diabetes is the defective development, activation or func-
tion of regulatory T cells [6–8]. Several subsets of regula-
tory T cells have the ability to suppress the proliferation 
and function of autoreactive T cells and prevent type 1 
diabetes development, including naturally occurring 
and induced populations of CD4+CD25+FoxP3+ T cells, 
CD8+ treg cells, NK T cells and CD4−CD8− (double-
negative, DN) T cells [9–13]. While currently, it is still a 
great challenge to reverse new diabetes successfully using 
adoptive cell therapy.
The DN T cells that are capable of downregulating 
the immune response comprise only 1–5 % of αβ T cell 
receptor (TCR)+ T cells in the peripheral lymphoid tis-
sue of normal mice and humans [14]. DN T cells also play 
a homeostatic role in autoimmune diabetes. Diabetes-
prone mice carry fewer DN T cells and this contributes to 
the increased susceptibility of these mice to developing 
the disease [15]. Moreover, peptide-activated antigen-
specific transgenic DN T cells can prevent autoimmune 
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from young non-obese diabetic (NOD) mice were dem-
onstrated to be able to induce long-lasting protection 
against diabetes subjected to an adoptive cell transfer 
protocol [16].
We identified a new differentiation pathway, by which 
a subset of proliferated CD4+ T cells converted to DN 
T cells after antigen-triggered or homeostatic prolifera-
tion in vitro and in vivo. Using this novel pathway, tens 
of millions of DN T cells can be rapidly produced [17]. 
We also reported that CD4+ T cells converted to pancre-
atic islet beta cell antigen-specific DN T cells can prevent 
the development of autoimmune diabetes and promote 
islet allograft survival in NOD mice [13]. Because DN 
T cells proliferated at very low levels in vitro and in vivo 
[17] and DN T cell inhibition on target cells was shown 
to be dependent on cell-cell contact [18], lymphodeple-
tion treatment to diminish pathogenic T cells population 
prior to DN T cell therapy might be an effective method 
to achieve more profound regulation.
In this study, we investigated the regulation of different 
subsets of T cells in vivo and in vitro by anti-thymocyte 
serum (ATS) and DN T cells. We also report the use of 
CD4+ T cell converted antigen-specific DN T cells in 
combination with ATS to suppress and reverse autoim-




Male C57BL/6 (H2b), C57BL/6 RAG−/− (H2b), C57BL/6 
congenic for CD45.1 (H2b), DBA/2 (H2d) and female 
NOD (H2g) were purchased from Vital River Laborato-
ries (Beijing, China) and the Jackson Laboratory (Bar 
Harbor, ME, USA). All mice were maintained in patho-
gen-free facilities at Beijing Friendship Hospital. All pro-
tocols were approved by the Institutional Animal Care 
and Ethics Committee.
Purification of CD4+ T cells, CD8+ T cells
Single-cell suspensions of mouse spleens and lymph 
nodes were prepared. CD4+ T cells were isolated by T 
cell enrichment column (R and D Systems, Minneapolis, 
MN, USA) followed by Ter119, B220, CD8, CD11b, TCR 
γδ, CD25 and NK1.1 positive cell depletion. CD8+ T cells 
were isolated by T cell enrichment column followed by 
Ter119, B220, CD4, CD11b, TCR γδ and NK1.1 positive 
cell depletion.
Conversion of DN T cells in vitro
Conversion of DN T cells in vitro was performed as pre-
viously described [13]. Briefly, mature dendritic cells 
(mDCs) were harvested from lipopolysaccharide-stim-
ulated bone marrow cells of DBA/2 or NOD mice, and 
separated by CD86-positive selection. C57BL/6 CD4+ 
T cells were incubated with DBA/2 mDCs with 50  ng/
ml rmIL-2 (Peprotech, Rocky Hill, NJ, USA). CD4+ T 
cells from NOD mice were cultured with NOD mDCs 
in the same conditions described above plus the addi-
tion of 1 µg/ml GAD65 peptides. CD3+CD4−CD8− DN 
fractions were isolated from mixed lymphocyte reaction 
(MLR) and sorted using a FACS (AriaII; BD Biosciences, 
San Diego, CA, USA).
In vitro suppression assays
Carboxyfluorescein diacetate succinimidyl ester (CFSE; 
Molecular Probes, Eugene, OR, USA) labeled CD4+ 
or CD8+ T cells (1  ×  105/well) from CD45.1 congenic 
C57BL/6 mice were co-cultured with DBA/2 mDCs 
(0.25 ×  105/well) for 4  days. The same amount of con-
verted B6 DN T cells were added to MLR as regulatory 
cells. CD4+ and CD8+ T cell proliferation was examined 
by flow cytometry.
ATS treatment in vitro
For ATS treatment of mouse splenocytes, freshly isolated 
cells were cultured in complete medium with 2 µl/ml of 
either ATS or rabbit serum (Accurate Chemical and Sci-
entific Corporation, Westbury, NY, USA). Twenty-four 
hours following culture initiation, splenocytes were har-
vested and TCR-β+, CD4+, CD8+ T and DN T cells were 
examined by flow cytometry.
ATS treatment in vivo
Eight-week-old NOD mice were treated with two intra-
peritoneal injections of ATS or rabbit serum (50  µl/
mouse) at day 0 and 2. Mice were monitored continu-
ously by examining TCR-β+, CD4+, CD8+ T and DN T 
cells in peripheral blood monocytes (PBMCs) using flow 
cytometry.
Adoptive transfer and skin transplantation
C57BL/6 DN T cells (1  ×  105) in combination with 
1 × 105 naive CD4+CD25− T cells or CD8+ T cells were 
transferred to C57BL/6 RAG−/− mice by tail vein injec-
tion. On the same day, full thickness 1 cm2 tail skin grafts 
from DBA/2 mice were transplanted to the C57BL/6 
RAG−/− mice. Graft survival was monitored by daily vis-
ual inspection. Graft rejection was defined as complete 
necrosis and loss of viable skin tissue.
Adoptive transfer and diabetes reversion
Mice were monitored for diabetes development by meas-
uring blood glucose levels twice weekly. Diabetes onset 
was defined as blood glucose levels of >12 mmol/L in two 
consecutive measurements. In the event of new-onset 
diabetes, two doses of 50 µl ATS were given to diabetic 
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NOD mice on day 0 and 2 by intraperitoneal injection. 
On day 7, ex vivo converted GAD65 primed DN T cells 
(1  ×  106) were transferred to ATS-treated mice by tail 
vein injection. Blood glucose levels of treated mice were 
inspected every other day.
Flow cytometric analysis
Cultured cells or PBMCs from treated mice were har-
vested at various time points and analyzed for prolifera-
tion or the expression of various cell surface markers. All 
samples were analyzed on an Aria II flow cytometer (BD 
Biosciences). Data was analyzed using FlowJo software 
(Treestar; FlowJo, Ashland, OR, USA).
Histologic examination
Pancreas were isolated 4 weeks after diabetes onset, and 
were fixed in 4 % paraformaldehyde, paraffin embedded, 
and sectioned. H and E staining was performed.
Statistical analysis
Analyses for statistically significant difference were per-
formed using the Student’s t test and one-way ANOVA 
test. The effects of DN T cells on diabetes reversion in 
the adoptive transferred models and the skin transplant 
model were statistically analyzed using a log-rank test. p 
values <0.05 were considered significant.
Results
CD4+ T cells converted DN T cells showed strong immune 
regulation on CD4+ T cells, but less suppression on CD8+ T 
cells both in vitro and in vivo
As shown in Fig.  1a, C57BL/6 DN T cells that were 
incubated with mature DBA/2 mDCs in  vitro potently 
suppressed C57BL/6 (CD45.1) CD4+ and CD8+ T cell 
proliferation triggered by the same alloantigens (DBA/2 
DCs) in  vitro. The inhibition efficacy of DN T cells on 
CD8+ T cells (46.2  %) was lower than that on CD4+ T 
cells (67.7  %) (Fig.  1b). The differences were more pro-
found in  vivo. Compared with control, significant 
prolongation of skin allograft survival on RAG−/− recipi-
ents occurred when equal numbers of DN T cells and 
CD4+CD25− T cells were co-transferred (Fig.  1c; mean 
graft survival time of 28 days vs 20.5 days; p = 0.0114). In 
contrast, DN T cells did not protect the skin graft rejec-
tion triggered by CD8+ T cells (Fig. 1d; p = 0.2857).
ATS treatment preferentially depleted CD8+ T cells 
while DN T cells were resistant to ATS both in vitro 
and in vivo
Both anti-thymocyte globulin (ATG) and ATS therapy 
can largely eliminate T cells from peripheral blood. It 
is debated whether ATG therapy preferentially depletes 
certain subsets of T cells. For instance, Xia et  al. [19] 
have reported that ATG depletes CD8+ T cells more 
efficiently than CD4+ T cells in both peripheral blood 
and lymphoid organs. We investigated changes of the 
absolute numbers and percentages of different T cell 
subsets in vitro. As shown in Fig. 2a, the percentage of 
CD3+TCR-β+ cells in splenocytes decreased from 44.7 
to 25.4  % with ATS treatment, and the absolute num-
ber of CD3+TCR-β+ cells also decreased significantly 
(Fig. 2b). The relative percentage of CD4+ T cells among 
the CD3+TCR-β+ lymphocytes changed from 65.2 to 
80.2  %, while CD8+ T cells (27.8–0.31  %) was almost 
eliminated by ATS treatment (Fig.  2a). Both absolute 
number of CD4+ and CD8+ T cells decreased, compared 
to CD4+ T cells, the absolute number of CD8+ T cells 
was more significantly decreased post-ATS treatment 
(Fig. 2c). Compared to the rabbit serum group, among all 
of the CD3+TCR-β+ lymphocytes, the ATS group dem-
onstrated a significantly increased percentage (6.21–
19 %) (Fig. 2a) and a similar absolute number of DN T 
cells (Fig. 2c), suggesting that DN T cells were resistant 
to ATS mediated depletion.
We monitored the post-ATS treatment depletion of dif-
ferent subsets of T cells in vivo. NOD mice were treated 
with two doses of ATS or rabbit serum (day 0 and 2), 
the percentages of different T cell subsets in the periph-
eral blood were examined (Fig. 3a). After treatment, we 
drew blood from each group (n  =  4) on the day indi-
cated in Fig. 3b–e. As shown in Fig. 3b, after ATS treat-
ment, the TCR-β+ T cells in the peripheral blood were 
nearly depleted on day 3 (from 30 to 0.03 %), but began 
to recover on day 12 and were still lower on day 30 com-
paring with the rabbit serum group. As shown in Fig. 3c, 
after ATS treatment, the CD4+ T cell percentage of the 
total TCR-β+ T cell pool dropped to its lowest level on 
day 3 (from 60 to 25 %), and began to recover afterwards 
and returned to a normal percentage of TCR-β+ T cell by 
day 12. Compared to the rabbit serum group, the CD8+ 
T cells dropped to their lowest levels in total TCR-β+ T 
cells 5 days after ATS therapy (from 40 to 5 %). The rela-
tive percentage of CD8+ T cells began to recover slowly 
after day 5, and remained significantly lower than the 
control group on day 30 (Fig. 3d). Interestingly, the pro-
portionate increase of DN T cells relative to the total 
TCR-β+ T cells (Fig. 3e) was found in ATS group on day 1 
and reached its peak on day 4 post-treatment.
The data above demonstrated that ATS strongly regu-
lates TCR-β+, CD4+ and CD8+ T cells both in  vitro 
and in  vivo. The most profound inhibition efficacy was 
observed against CD8+ T cells. In contrast, the in  vitro 
and in vivo data showed that DN T cells were resistant to 
ATS mediated depletion.
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Fig. 1 DN T cells showed different immune regulation of CD4+ and CD8+ T cells in vitro and in vivo. a DN T cells potently suppressed CFSE-labeled 
CD4+ and CD8+ T cell proliferation triggered by mDCs in vitro. The horizontal bars gate the un-dividing cells, and the numbers refer to the percent-
ages these cells comprise of the total CD4+ or CD8+ T cells respectively. b The data are shown as percent inhibition of proliferation compared with 
controls, to which no DN T cells were added. The results reported are representative of three experiments with similar results. c The rejection of a 
skin graft from DBA/2 mice transplanted to C57BL/6 RAG−/− mice was induced by adoptive transfer of naïve C57BL/6 CD4+CD25− T cells or CD8+ 
T cells. C57BL/6 DN T cells were co-transferred by tail vein injection. Graft survival was observed by daily visual inspection. DN T cells suppressed 
naïve CD4+CD25− T cell-triggered skin allograft rejection. d DN T cells failed to prolong naïve CD8+ T cell-triggered skin allograft rejection. Statistical 
analysis was performed using a log-rank test
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Combined ATS and DN T cell treatment resulted 
in significant reversion of new‑onset autoimmune diabetes 
in NOD mice
DN T cells did not efficiently suppress CD8+ T cells 
in  vivo, while ATS significantly depleted CD8+ T cells 
but had no strong effects on DN T cells. We therefore 
explored whether the combination of ATS treatment 
with CD4+ T cell converted DN T cells could reverse new 
onset type 1 diabetes in NOD mice. Two doses of ATS 
were given to diabetic NOD mice on day 0 and day 2 after 
diabetes onset by intraperitoneal injection. On day 7, 
1 ×  106 ex vivo GAD65 primed DN T cells were trans-
ferred to the ATS treated mice by tail vein injection.
Twenty-one days after diabetes onset, 80 % of the dia-
betic NOD mice (n = 6) that received the combined ATS 
and DN T cell treatment achieved autoimmune diabe-
tes reversion that lasted for at least 6 months (Fig. 4A). 
In contrast, a single transfer of an equivalent amount of 
GAD65 primed DN T cells was unable to induce rever-
sion of hyperglycemia in any recipient (n  =  5). ATS 
induction therapy alone (n = 12) resulted in a 16 % rever-
sion of hyperglycemia in all recipients. These data suggest 
that ATS induction therapy significantly promotes DN T 
cell efficacy in reversing autoimmune diabetes.
Histopathological changes were assessed in H and 
E-stained pancreas sections from NOD recipients 
28  days after diabetes onset in each group (Fig.  4B). A 
massive mononuclear cells infiltration of the islets with 
loss of islet structure was observed in the no treatment 
group (a). Fewer mononuclear cells infiltration of the 
islets were observed in diabetic NOD mice that received 
either ATS or 1 × 106 DN T cells alone (b and c). In con-
trast, pancreas sections from NOD mice given 1 ×  106 
DN T cells in combination with ATS treatment (d) 
showed normal islet structure without obvious mononu-
clear cell infiltration.
After combined ATS plus DN T cell treatment in NOD mice, 
the percentage of DN T cells in spleen and pancreatic 
draining lymph nodes (LN) is significantly higher than that 
in mesenteric LN
To gain further understanding of the distribution of DN 
T cells in diabetic NOD mice cured by combined ATS 
plus DN T cell treatment, we investigated the percentage 
of DN T cells in different peripheral lymphoid tissues. As 
indicated in Fig. 5, the percentage of DN T cells in spleen 
and pancreatic draining lymph nodes (LN) is relatively 
higher in all groups than in mesenteric LN. Six months 
after combined ATS and DN T cell treatment, the per-
centage of DN T cells (10.4 % in draining LN, 16.8 % in 
the spleen) is higher in treated mice than in diabetes free 
control (7.25 % in draining LN, 7.64 % in the spleen) or 
diabetic NOD mice that received no treatment (6.35 % in 
draining LN, 8.61 % in the spleen). Compared with dia-
betes free control or diabetic NOD mice that received 
no treatment, in the combined treatment group, the per-
centage of DN T cells in draining LN (10.4  %) and the 
spleen (16.8 %) is significantly higher than the percentage 
in mesenteric LN (4.79 %). Additionally, the suppression 
of CD8+ T cells in spleen is still significant 6 months after 
Fig. 2 ATS treatment differentially depletes T cells from spleen after 
24 h in vitro. C57BL/6 splenocytes were cultured with 2 µl/ml ATS or 
rabbit serum and a the percentage of TCR-β+, CD4+, CD8+ and DN 
T cells were evaluated 24 h later by flow cytometry. The numbers in 
the left panels refer to the percentages of CD3+TCR-β+ cells in the 
total lymphocyte pool, the numbers in the right panels refer to the 
percentages of CD4+,CD8+ and DN T cells among the CD3+TCR-β+ 
lymphocytes. Data are representative of three experiments per-
formed with similar results. b Absolute numbers of splenocytes and 
CD3+TCR-β+ T cells 24 h following the initiation of the cultures. c 
Absolute numbers of CD4+, CD8+ and DN T cells 24 h following 
the initiation of the cultures. Data shown are the means (±standard 
deviation [SD]) of three separate experiments
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Fig. 3 ATS treatment differentially depletes T cells from the peripheral blood in vivo. NOD mice were treated with ATS or rabbit serum and the 
percentage of TCR-β+, CD4+, CD8+ and DN T cells in the peripheral blood was examined by flow cytometry. a The flow cytometry results at day 
9 after the first ATS treatment indicate the measurement of the percentage of different T cell subsets. The numbers in the left panels refer to the 
percentages of lymphocytes in the total PBMC, the numbers in the middle panels refer to the percentages of CD3+TCR-β+ cells in the total lympho-
cyte pool and the numbers in the right panels refer to the percentages of CD4+, CD8+ and DN T cells among the CD3+TCR-β+ lymphocytes. T cell 
subsets (based on flow cytometry analysis) from the peripheral blood were followed for 30 days after two doses of ATS. (n = 4 in each group). b The 
percentage of CD3+TCR-β+ cells in the total lymphocyte pool. c The percentage of CD4+ T cells among the CD3+TCR-β+ T cells. d The percentage 
of CD8+ T cells among the CD3+TCR-β+ T cells. e The percentage of CD4−CD8− DN T cells among the CD3+TCR-β+ T cells
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treatment. This suggests that combined treatment leads 
to long-term suppression of CD8+ T cells.
Discussion
Type 1 diabetes develops when the insulin-secreting beta 
cells are destroyed by infiltrating T cells. Autoreactive T 
cells, both CD4+ and CD8+ cells, have been implicated 
as active players in beta-cell destruction [2–5, 20]. Thus, 
a treatment strategy that targets both CD4+ as well as 
CD8+ T cells may be able to induce immunological toler-
ance to beta cells.
Studies reveal that DN T cells are potent T cells sup-
pressors [15, 21, 22]. We previously demonstrated that 
CD4+ T cell converted DN T cells blocked autoimmun-
ity and prevented diabetic onset in NOD mouse models. 
These effects were even greater when using islet beta cell 
antigen-specific DN T cells. However, reversing new-
onset autoimmune diabetes was a more daunting chal-
lenge. A single transfer of 4 × 106 DN T cells only slightly 
postponed the progression of hyperglycemia in new-
onset autoimmune diabetic mice [13]. In this study, the 
efficacy of inhibition of DN T cells on CD8+ T cells was 
lower than on CD4+ T cells in vitro. Furthermore, the co-
transfer of DN T cells did not protect against CD8+ T cell 
triggered skin graft rejection. These results indicate that 
inefficient CD8+ T cells suppression in vivo may be one 
of the reasons underlying the failure of DN T cells to con-
trol autoimmunity in new-onset diabetic NOD mice. The 
failure of these trials has led to efforts to more directly 
shift the balance from destructive a T cell response to 
regulatory T cell control [23].
ATG is a common immunosuppressive reagent used 
in allogeneic transplantation [24–26] and autoimmune 
disorders [27–31]. ATS is a polyclonal rabbit anti-mouse 
thymocyte product that is similar in action to ATG and 
that effectively depletes peripheral blood T cells in  vivo 
[32]. Spontaneous diabetes in female mice was sup-
pressed by ATS [33]. ATG therapy functions through 
complement mediated depletion of mature T cells, while 
tregs were less sensitive to ATG depletion [19]. How-
ever, researchers found that a brief course of ATG ther-
apy does not result in the preservation of β-cell function 
12  months after the treatment course in patients with 
new-onset type 1 diabetes [34]. Furthermore, ATG does 
not reverse type 1 diabetes in the acute virally induced 
rat insulin promoter-lymphocytic choriomeningitis virus 
(RIP-LCMV) model [35].
In line with previous reports, we found that ATS ther-
apy markedly depleted TCR-β+, CD4+ and CD8+ T cells. 
Among these cell types, CD8+ T cells were the most sen-
sitive to ATS depletion. We report, for the first time, that 
DN T cells are, like Tregs, less sensitive to ATS deple-
tion and make up a dramatically increased percentage of 
the post-treatment cell population. These results could 
explain why ATS induction therapy resulted in a 16  % 
reversion of hyperglycemia in new-onset diabetic NOD 
mice.
Our data suggest that ATS markedly suppresses CD8+ T 
cells and selectively preserves the DN T cell population. We 
also demonstrated that converted DN T cells have a strong 
ability to regulate pathogenic CD4+ T cells but a lesser abil-
ity to suppress CD8+ T cells. We then assessed the ability of 
combined ATS induction and DN T cell therapy to shift the 
balance away from a destructive T cell response towards a 
DN T cell regulated response in new-onset diabetic mice. 
After the ATS treatment has reduced the levels of both 
CD4+ and CD8+ T cells, GAD65 primed DN T cells that 
were converted from CD4+ T cells in vitro were transferred 
7 days after diabetes onset. In 21 days, the combined treat-
ment achieved long term reversion of autoimmune diabe-
tes in most of the new-onset diabetic NOD mice (80  %). 
However, an equivalent amount of GAD65-primed DN T 
cells resulted in no reversal of hyperglycemia. When used 
alone to treat new-onset diabetic NOD mice, ATS induc-
tion only resulted in a 16 % reversion of hyperglycemia.
Fig. 4 Reversion of autoimmune diabetes in new-onset type 1 dia-
betes NOD mice. A At the onset of diabetes, two doses of 50 µl ATS 
were given to diabetic NOD mice on day 0 and day 2 by intraperito-
neal injection. On day 7, ex vivo converted GAD65 primed DN T cells 
(1 × 106) were transferred to ATS-treated mice by tail vein injection. 
Mice were monitored for the diabetes reversion by measuring blood 
glucose levels. Statistical analysis was performed using a log-rank test. 
B Histological analysis of islets from different groups. Routine H and 
E staining of pancreas isolated 4 weeks after diabetes onset. Massive 
tissue infiltration by mononuclear cells with destruction of islets is 
observed in mice without treatment (a), with two doses of ATS treat-
ment (b), DN T cells alone (c) and combination treatment of DN T cells 
plus ATS show intact islets with minimal mononuclear cell infiltration 
(d). Paraffin sections, original magnification× 400
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Treg homing in secondary lymphoid tissues is required 
for the functional clustering of tregs with APCs and T cells 
that is necessary for the induction and maintenance of 
immunological tolerance [36, 37]. We first report that DN 
T cells preferentially migrate to the spleen and pancreatic 
draining LN. Six months after ATS plus DN T cell treat-
ment, the percentage of DN T cells in mice receiving the 
combined treatment is higher than that observed in both 
diabetes free mice and diabetic NOD mice without treat-
ment. In the combined treatment group, the percentage of 
DN T cells in draining LN and the spleen is significantly 
higher than that found in mesenteric LN. This indicates 
that islet specific DN T cells migrated to the pancreatic 
draining LN and spleen and protected the islets’ beta cells 
from destruction by pathogenic T cells, but that DN T cells 
did not migrate to other unrelated lymphoid organs. Addi-
tionally, combined treatment induced long-term suppres-
sion of CD8+ T cells. Taking into consideration the major 
role that CD8+ T cells play in autoimmune diabetes, the 
potent and long-term suppression of CD8+ T cells by DN 
T cells is likely one of the reasons for the long-term rever-
sion of diabetes caused by the combined treatment.
Conclusions
The combination of transient T cell depletion by ATS 
with adoptive transfer of ex vivo CD4+ T cell converted 
DN T cells leads to a long term reversal of new-onset dia-
betes in NOD mice. The improvement of outcome is due 
to a shift of balance from a destructive T cell response to 
one that favors DN T cell regulation. The results reported 
by this study support the concept and the potential 
feasibility of utilizing this novel cell-based therapeu-
tic approach for the treatment of autoimmune type 1 
diabetes.
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